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Introduction 
During the last decade the most widely favoured 
management for aortic graft infection required a rad- 
ical approach with total graft removal, aortic stump 
closure, and extra-anatomic grafting through un- 
infected tissues. 14 Staging of the procedures - initial 
extra-anatomic bypass followed by either immediate 
or interval graft excision vs. the more traditional single 
operation of graft excision followed by lower extremity 
revascularisation - seems to give the best results. 3
Unfortunately, this management strategy results in 
several significant problems. Extra-anatomic bypass 
patency rates can be very disappointing, in particular 
in patients with extensive vascular occlusive disease 
who require axillounilateral profunda or popliteal by- 
passes. In addition to the high rate of thrombosis, 
recurrence of infection in an extra-anatomic bypass 
graft occurs in about 20% of cases. 9 Aortic stump 
blowout is still an unresolved issue. Although recent 
studies have shown that the risk of disruption of 
the aortic closure is minimised by careful surgical 
technique, 7 it continues to be a much feared and fre- 
quently quoted early and late problem, with an in- 
cidence of 20% or more. 3'1° Stump blowout is almost 
always fatal and reinfection of extra-anatomic pros- 
thetic grafts often causes limb loss or death. 
In situ graft reconstruction has been reported as an 
attractive treatment alternative because of its relative 
technical ease, theoretically better long-term patency 
rates, and potential avoidance of aortic stump blow- 
out.~ ~a Although it can be a rational treatment option 
for localised or circumscribed aortic infection, it does 
not seem reasonable in the case of diffusely infected 
* Please address all correspondence to: E. Kieffer, Service de Chi- 
rurgie Vasculaire, Groupe Hospitalier Piti6-Salp@tri6re, 47-83 bou- 
levard e I'H6pital, 75013 Paris, France. 
abdominal aortic prosthetic grafts, where graft re- 
moval and extra-anatomic grafting are required. 13 Fur- 
thermore, placing a prosthesis in a contaminated field 
surely risks reinfection of the graft, with early recurrent 
rupture or false aneurysm of the proximal aortic 
anastomosis. 12 
Towne et al. 14 have emphasised the subtle clinical 
presentation ofpatients with Staphylococcus epidermidis 
graft infections. The low virulence of this organism 
permits treatment by partial excision of the grossly 
involved graft segments, debridement of perigraft is- 
sue and adjacent artery, and in situ replacement of 
another prosthesis. Conversely, according to these au- 
thors in situ replacement for Gram-negative infection 
and for coagulase-positive staphylococcus infections 
is not recommended, and subsequent infection of pre- 
viously uninvolved graft segments may be expected. 
Experimental studies 1~ have shown that collagen 
rifampicin-bonded grafts reduce the incidence of graft 
colonisation after in situ replacement of an infected 
graft. Based on these excellent results, gelatin-sealed 
grafts soaked with rifampicin were implanted in situ 
in five patients with aortic prosthetic infection not 
suitable for graft excision and extra-anatomic bypass. ~6 
Despite promising early results, further observation 
of the patients is necessary to exclude recurrent graft 
infection. Also, grafts infected with bacteria resistent 
to rifampicin remain an unresolved issue. 
A controversial strategy including complete graft 
preservation totreat selected aortobifemoral prosthetic 
graft infection has been recently reported. ~7 Pre- 
servation of the entire graft is only recommended 
when the graft is patent, the anastomoses are intact, 
the patient does not have sepsis, and cultures of the 
wound do not yield pseudomonas. Treatment adjuncts 
include repeated, radical operative wound de- 
bridement and rarely rotational muscle flaps. Once 
again, in case of anastomotic haemorrage, graft throm- 
bosis, or persistent drainage of purulent material the 
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authors advocate graft excision and extra-anatomic 
bypass. The limited number of patients with aortic 
prosthetic infections so treated does not allow any 
firm conclusions to be drawn. 
In order to avoid the risk of persistent or recurrent 
graft infection and the hazards of aortic stump com- 
plications, different types of autogenous recon- 
structions have been reported. ~8-22 The autogenous 
approach was originally advocated by Ehrenfeld et 
al., TM who reported reconstructing the aortoiliac seg- 
ments by disobliterating occluded aortoiliac segments, 
coupled with arterial and venous autografts, after 
extensive debridement of the infected area. However, 
the presence of degenerative or aneurysmal changes 
in the native arterial segments contraindicating end- 
arterectomy and the lack of suitable greater saphenous 
veins (GSV) limit the use of these procedures, which 
are always technically demanding. The risk of sec- 
ondary failure of disobliterated arterial segments and 
GSV is also a major concern. 2°'2~ More recently, the use 
of GSV alone, 19 lower extremity deep veins (DV) 
alone, 22 or both GSV and DV 21 has been reported. 
Harvesting of DV was well tolerated, without disabling 
chronic venous stasis, although it is obviously contra- 
indicated in cases of previous deep venous thrombosis. 
Furthermore, the use of GSV has been associated with 
development of focal stenoses and diffuse neointimal 
hyperplasia. 21 The possibility of future dilatation of 
thin wall DV in an aortic position can also be expected. 
Arterial allografts 
Allograft aortic replacement is not a new technique. 
Experimental studies were carried out by Carrel 23 early 
in this century and the first clinical use goes back to the 
early years of vascular surgery. 24"25 Although clinical 
results were encouraging, several drawbacks were 
soon recognised. 
Despite the organisation of arterial banks, pro- 
curement and preservation of human allografts were 
fraught with difficulties. The available methods of 
sterilisation and storage were certainly a major con- 
tributing factor to the secondary dilatation and cal- 
cification observed in a significant number of 
patients. 26'27 Finally, the development of suitable ar- 
terial prostheses led to abandonment of arterial 
allografts in the early 1960s. Prosthetic infection 
soon appeared, however, as a rare but dreadful 
complication. 
During the last two decades our policy for the 
treatment of this devastating complication shifted from 
partial graft removal to total graft removal, associated 
with lower limb revascularisation by either extra-ana- 
tomic bypasses or in situ autogenous reconstructions. 
Despite a progressive decrease in mortality and mor- 
bidity, our experience of these conventional methods 
of treatment was disappointing. Encouraged by the 
excellent long-term results reported by cardiac sur- 
geons following allograft replacement for management 
of infections involving the ascending aorta 23'29 and 
from a very active local multi-organ transplant tissue 
retrieval program, we decided to investigate allograft 
replacement in the management of arterial infections. 
Our first patient was operated upon in October 
19883o and a series of 43 consecutive patients was 
reported in 1993. 31 As of October 1995, 100 consecutive 
patients with infected infrarenal aortic prosthetic grafts 
underwent in situ replacement with preserved al- 
lografts in our department. 32 Twenty-seven patients 
had a graft-enteric fistula. Twenty-six patients needed 
emergency procedures because of acute bleeding, sep- 
tic complications and/or lower limb ischaemia, while 
74 patients had planned operations. 
Technique 
Our technique of procurement and preservation of 
allografts has been previously described. 31Arterial 
allografts were harvested from cadavers as part of a 
multi-organ transplant tissue retrieval program. Bac- 
teriology and virology tests were routinely performed 
among donors. The whole length of the descending 
thoracic aorta, aortic bifurcation, iliac and femoral 
arteries were obtained. Hypogastric and deep femoral 
arteries were transected 2-3 cm distal to their origins in 
order to allow revascularisation f the corresponding 
arteries of the recipient. A fragment of the retrieved 
arterial allograft was routinely cultured for bac- 
teriological control. Allografts were stored in 500 ml 
of preservation medium containing heparin and anti- 
biotics. Allografts were implanted after a minimum 
interval of 48 h, to decrease cellular antigenicity and 
a maximum interval of 21 days, to avoid late de- 
generative changes. Because of the limited number of 
available allografts, matching blood and tissue com- 
patibility between recipient and donor was not 
attempted. 
Before implantation a fragment of allograft and a 
few millilitres of the preservation medium were sent 
to the bacteriology laboratory. The aortic stump and 
periprosthetic infected tissues were carefully debrided. 
The periprosthetic fluid and part of the infected pros- 
thetic graft were sent for bacteriological culture. The 
allograft was implanted in situ, using polypropylene 
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Fig. 1. Postoperative aortography showing an aortobifemoral - 
lograft and a retrograde saphenous vein graft to the superior mes- 
enteric artery. 
running sutures for proximal and distal anastomoses. 
All infected prosthetic material was usually removed 
at the same operation. Associated reconstructions of 
lower limb and/or visceral arteries were performed 
in a significant number of patients (Figs. 1 and 2). 
Retroperitoneal nd inguinal drainage were used 
routinely. 
All patients received broad-spectrum antibiotics 
perioperatively that were replaced by selective anti- 
biotics according to culture results. Antibiotics were 
maintained for at least 6 weeks. None of the patients 
received long-term or indefinite antibiotic therapy. 
Results 
Twenty-four patients died during the early post- 
operative period. More than half of deaths were due 
to septic complications. The overall mortality of the 
present series (24%) is quite disappointing, compared 
to the 12% mortality among the 43 patients we reported 
in 1993. However, in the present series mortality rate 
was 38% in patients with aortoenteric fistulas, and 
19% in patients with isolated prosthetic nfection. Even 
Fig. 2. Postoperative aortography showing an aortobifemoral - 
lograft, with direct reconstruction of the left internal iliac artery. 
more striking was the difference of mortality rates 
among patients undergoing emergency operations be- 
cause of haemorragic, septic or ischaemic com- 
plications, and patients undergoing planned 
operations (46% vs. 16%, respectively). All surviving 
patients had postoperative arteriography before dis- 
charge. Routine follow-up included duplex scanning 
at 3-monthly intervals. Late computed tomography 
(CT) scanning and/or aortography were performed 
depending upon the results of duplex scanning. There 
were 13 late deaths, of whom two were due to aortic 
rupture. During follow-up 20 occlusive lesions were 
observed and 15 required reoperation which was al- 
ways successful. Ultrasonography and CT scanning 
showed aortic dilatation with mural thrombosis n five 
patients. In all of these cases descending thoracic 
aortic allografts had been used for replacement of
the infrarenal aorta. As of yet, none have had to be 
reoperated upon. Three patients had major am- 
putations because of pre-existing irreversible ischemia. 
No patients had secondary amputations. 
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Discussion 
Although the overall survival rates of our series are 
less promising than our preliminary experience, 31 in 
situ allograft replacement has several undeniable ad- 
vantages in the management of infected infrarenal 
aortic prosthetic grafts. Experimental studies 33 sug- 
gested that fresh allograft arteries are suitable materials 
for arterial reconstruction i infected fields because 
they function as a vascular conduit and allow res- 
olution of infection by conventional ntibiotic therapy. 
This avoids complications related to aortic stump path- 
ology as well as occlusion or infection of prosthetic 
extraanatomic bypasses. 34The risk of persistent or 
recurrent infection of in situ prosthetic replacement is 
also significantly reduced, even though not completely 
eliminated. Furthermore, availability of long bi- 
furcated grafts makes the procedure feasible in all 
cases and technically much easier than autogenous in 
situ reconstructions u ing endarterectomy, venous or 
arterial autografts or a combination of these. 18 As- 
sociated visceral reconstructions, if indicated, are also 
feasible. More importantly, there were no early or late 
amputations in our patients econdary to failure of 
arterial allograft reconstruction, an outcome not 
matched by any of the conventional methods. Never- 
theless, arterial allograft replacement raises several 
theoretical s well as practical problems: 
1) Availability of arterial allografts is rather limited at 
present, because of donor shortage and legal problems. 
The organisation of arterial banks has just begun and 
will probably develop in the next years. However, 
according to experimental s well as clinical studies, 
there is no hard evidence to choose between fresh 
allografts stored at 4°C in a preservation medium, 
which we used to reduce allograft antigenicity, and 
cryopreserved grafts, which have the distinct ad- 
vantage of avoiding all risks of viral contamination. 
2) Perioperative mortality of in situ arterial allograft 
replacement remains high and is by far greater than 
mortality of prosthetic aortic replacement in a non- 
infected field. Aortic allograft replacement can be a 
rather aggressive operation, entailing a repeat lap- 
arotomy, the possibility of significant blood loss and 
long operative times along with the necessity of sup- 
rarenal clamping in a significant number of cases. 
Unfortunately, patient selection is difficult due to the 
unfavourable outcome of spontaneously evolving 
prosthetic nfections and the need for emergency oper- 
ation in case of haemorragic, ischaemic or septic com- 
plications. Some of our patients, in poor general 
condition, without emergency indications might have 
benefited from a two-stage operation, including local 
treatment of the main complications (drainage of 
closed collections, direct suture of leaking ana- 
stomoses, direct suture repair of enteric fistulas), with 
allograft aortic replacement and removal of all pros- 
thetic materials performed as a secondary procedure 
after adequate preparation of the patient. Septic shock 
was the leading cause of mortality in our series. 
Patients usually had long-standing infections sec- 
ondary to multiple multi-resistant organisms, in- 
cluding mycobacteria and fungi, and had undergone 
multiple redo palliative operations. Of the utmost 
importance, therefore, is early treatment of the patient 
as soon as signs of prosthetic infection appear, and 
replacement of broad-spectrum antibiotics by selective 
antibiotics, according to cultures from blood, perigraft 
collections, and infected graft fabric. 
3) Resistance of allograft o infection cannot be con- 
sidered complete, specially when dealing with highly 
virulent organisms and incompletely debrided infected 
tissues. In our series one patient died 13 days post- 
operatively from septic rupture of his native aorta 
proximal to the allograft anastomosis, probably be- 
cause of highly virulent infection and insufficient de- 
bridement of the infected aorta. Besides appropriate 
antibiotic therapy, coverage of the aortic allograft with 
viable tissue such as omentum or rotational muscle 
flaps as well as drainage or even continuous irrigation 
of contaminated fields with antibiotics or povidone- 
iodine solution, are all important adjuncts to eradicate 
infection. 
4) Long-term results of arterial allografts are still a 
cause for concern. Although the methods of allograft 
procurement and storage are at present totally different 
from those utilised in the 1950s, the risks of allograft 
degenerative changes cannot be overlooked. All of 
our patients had routine duplex scanning during the 
follow-up. CT scanning and/or aortography were per- 
formed epending on the results of ultrasound studies. 
Dilatation of the allograft was observed in only a few 
patients in whom thoracic aortic allografts (elastic 
arteries), had been used for replacement of the in- 
frarenal aorta. None has yet been reoperated upon. 
However, at 2 years of follow-up, occlusive lesions 
were observed in about 25% of external iliac and 
femoral arterial allografts (muscular arteries), re- 
quiring redo operations for ischaemic symptoms. Al- 
though the cause was probably intimal hyperplasia in
the majority of cases, typical histological signs of 
chronic rejection were observed, i.e. intimal pro- 
liferation of myofibroblastic ells, medial smooth 
muscle necrosis and adventitial inflammatory cells 
infiltration. Secondary and late deterioration of al- 
lografts, therefore, are probably partly immunological 
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in origin. 3536 Matching of blood and histocompatibility 
between recipient and donor was not attempted in 
our series because of the lack of available allografts. 
The development of arterial banks should make this 
possible in the near future. Although immuno- 
suppressive treatment can delay intimal thickening s6
and improve long-term patency of arterial allografts, 
37 it is obviously contraindicated in infected patients. 
Conclusions 
The use of arterial allografts is certainly not the "ideal" 
solution for the treatment ofaortic prosthesis nfection. 
In situ reconstructions with either autogenous DV or 
antibiotic-bonded grafts may be valuable alternatives, 
even though further evaluation of these materials is 
needed. Nevertheless, arterial allografts deserve on- 
going research, regarding their resistance to infection, 
antigenicity, mechanical properties and preservation 
techniques, in order to better understand their bio- 
logical behaviour and better define the indications 
and modalities for their clinical use. Our results have 
encouraged us to continue to offer in situ allograft 
replacement to patients with abdominal aortic infected 
grafts. 
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